BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Feb 11, 2023
Product Development

Feb. 10 Quick Takes: Aristea dissolving after safety findings

Plus: Abecma more than triples PFS in triple-class MM, and updates from Genentech, Phathom, Blueprint and more
BioCentury | Apr 1, 2022
Distillery Therapeutics

Blocking CXCL1 signaling for hand, foot and mouth neuropathology

BioCentury | Jul 27, 2021
Deals

Aristea plots path forward in rare skin disease with $63M series B, Arena deal

Arena obtains option to acquire well-funded AZ spinout after palmoplantar pustulosis readout
BioCentury | Mar 9, 2021
Product Development

Palmoplantar pustulosis pipeline: Data Byte

AnaptysBio’s Phase II miss for palmoplantar pustulosis (PPP) may indicate that overactive IL-36 signaling is not the dominant driver of the disease. The news could be a warning for
BioCentury | Oct 2, 2020
Distillery Therapeutics

Targeting CXCL1 signaling for HSV-1 encephalitis

DISEASE CATEGORY: Infectious disease
INDICATION: Encephalitis; herpes simplex virus (HSV) Inhibiting CXCL1 or its receptor, CXCR2, could treat encephalitis caused by HSV-1. In mice with HSV-1
BioCentury | Jun 14, 2018
Translation in Brief

There’s more to MIF

How MIF, sCD74 could prevent or treat AKI after cardiac surgery
BioCentury | Apr 13, 2018
Targets & Mechanisms

Meeting the burden

New developments in TMB, synthetic lethality, oncolytic viruses & more at AACR18
Items per page:
1 - 10 of 38